조직공학 시장 규모, 점유율, 동향 분석 보고서 : 용도별, 지역별 및 부문별 예측(2026-2033년)

Tissue Engineering Market Summary

The global tissue engineering market size was valued at USD 22.1 billion in 2025 and is projected to grow from USD 25.3 billion in 2026 to USD 64.2 billion by 2033, growing at a CAGR of 14.2% from 2026 to 2033. The North America market held the largest share of 50.8% of the global market in 2025. The growing demand for regenerative medicine, the rising prevalence of chronic diseases, and ongoing advances in biomaterials, stem cell research, and 3D bioprinting are driving market growth.

Global Tissue Engineering Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global tissue engineering market based on application and region:

• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Cord blood & Cell Banking
• Cancer
• GI, Gynecology
• Dental
• Skin & Integumentary
• Urology
• Orthopedics, Musculoskeletal, & Spine
• Neurology
• Cardiology & Vascular
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • Thailand
  • South Korea
• Latin America
  • Brazil
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Application
  • 1.1.2. Regional scope
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.3.1. Purchased database
  • 1.3.2. GVR's internal database
  • 1.3.3. Secondary sources
  • 1.3.4. Primary research
  • 1.3.5. Details of primary research
• 1.4. Information or Data Analysis
  • 1.4.1. Data analysis models
• 1.5. Market Formulation & Validation
• 1.6. Model Details
  • 1.6.1.1. Commodity flow analysis (Model 1)
  • 1.6.1.2. Approach 1: Commodity flow approach
• 1.7. List of Secondary Sources
• 1.8. List of Primary Sources
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Tissue Engineering Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Advancements in regenerative medicine
    • 3.2.1.2. Increasing prevalence of chronic diseases and traumatic injuries
    • 3.2.1.3. Growing investments in stem cell and cell & gene therapy research
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. High cost of tissue-engineered products and regenerative therapies
    • 3.2.2.2. Ethical concerns related to stem cell research & tissue-engineered products
• 3.3. Tissue Engineering Market Analysis Tools
  • 3.3.1. Porter's Five Forces Analysis
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTLE Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Social landscape
    • 3.3.2.4. Economic landscape
    • 3.3.2.5. Legal landscape

Chapter 4. Application Business Analysis

• 4.1. Segment Dashboard
• 4.2. Global Tissue Engineering Market Application Movement Analysis
• 4.3. Global Tissue Engineering Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Billion)
• 4.4. Cord blood & Cell banking
  • 4.4.1. Cord blood & cell banking market estimates and forecast, 2021 - 2033 (USD Billion)
• 4.5. Cancer
  • 4.5.1. Cancer market estimates and forecast, 2021 - 2033 (USD Billion)
• 4.6. GI, Gynecology
  • 4.6.1. GI, gynecology therapy market estimates and forecast, 2021 - 2033 (USD Billion)
• 4.7. Dental
  • 4.7.1. Dental market estimates and forecast, 2021 - 2033 (USD Billion)
• 4.8. Skin & Integumentary
  • 4.8.1. Skin & integumentary market estimates and forecast, 2021 - 2033 (USD Billion)
• 4.9. Urology
  • 4.9.1. Urology market estimates and forecast, 2021 - 2033 (USD Billion)
• 4.10. Orthopedics, Musculoskeletal, & Spine
  • 4.10.1. Orthopedics, musculoskeletal, & spine market estimates and forecast, 2021 - 2033 (USD Billion)
• 4.11. Neurology
  • 4.11.1. Neurology market estimates and forecast, 2021 - 2033 (USD Billion)
• 4.12. Cardiology & Vascular
  • 4.12.1. Cardiology & vascular market estimates and forecast, 2021 - 2033 (USD Billion)
• 4.13. Others
  • 4.13.1. Others market estimates and forecast, 2021 - 2033 (USD Billion)

Chapter 5. Regional Business Analysis

• 5.1. Regional Dashboard
• 5.2. Tissue Engineering Market: Share By Region, 2025 & 2033
• 5.3. North America
  • 5.3.1. North America Tissue Engineering Market, 2021 - 2033 (USD Billion)
  • 5.3.2. U.S.
    • 5.3.2.1. Key Country Dynamics
    • 5.3.2.2. Competitive Scenario
    • 5.3.2.3. Regulatory Framework
    • 5.3.2.4. U.S. Tissue Engineering Market, 2021 - 2033 (USD Billion)
  • 5.3.3. Canada
    • 5.3.3.1. Key Country Dynamics
    • 5.3.3.2. Competitive Scenario
    • 5.3.3.3. Regulatory Framework
    • 5.3.3.4. Canada Tissue Engineering Market, 2021 - 2033 (USD Billion)
  • 5.3.4. Mexico
    • 5.3.4.1. Key Country Dynamics
    • 5.3.4.2. Competitive Scenario
    • 5.3.4.3. Regulatory Framework
    • 5.3.4.4. Mexico Tissue Engineering Market, 2021 - 2033 (USD Billion)
• 5.4. Europe
  • 5.4.1. Europe Tissue Engineering Market, 2021 - 2033 (USD Billion)
  • 5.4.2. UK
    • 5.4.2.1. Key Country Dynamics
    • 5.4.2.2. Competitive Scenario
    • 5.4.2.3. Regulatory Framework
    • 5.4.2.4. UK Tissue Engineering Market, 2021 - 2033 (USD Billion)
  • 5.4.3. Germany
    • 5.4.3.1. Key Country Dynamics
    • 5.4.3.2. Competitive Scenario
    • 5.4.3.3. Regulatory Framework
    • 5.4.3.4. Germany Tissue Engineering Market, 2021 - 2033 (USD Billion)
  • 5.4.4. France
    • 5.4.4.1. Key Country Dynamics
    • 5.4.4.2. Competitive Scenario
    • 5.4.4.3. Regulatory Framework
    • 5.4.4.4. France Tissue Engineering Market, 2021 - 2033 (USD Billion)
  • 5.4.5. Italy
    • 5.4.5.1. Key Country Dynamics
    • 5.4.5.2. Competitive Scenario
    • 5.4.5.3. Regulatory Framework
    • 5.4.5.4. Italy Tissue Engineering Market, 2021 - 2033 (USD Billion)
  • 5.4.6. Spain
    • 5.4.6.1. Key Country Dynamics
    • 5.4.6.2. Competitive Scenario
    • 5.4.6.3. Regulatory Framework
    • 5.4.6.4. Spain Tissue Engineering Market, 2021 - 2033 (USD Billion)
  • 5.4.7. Sweden
    • 5.4.7.1. Key Country Dynamics
    • 5.4.7.2. Competitive Scenario
    • 5.4.7.3. Regulatory Framework
    • 5.4.7.4. Sweden Tissue Engineering Market, 2021 - 2033 (USD Billion)
  • 5.4.8. Norway
    • 5.4.8.1. Key Country Dynamics
    • 5.4.8.2. Competitive Scenario
    • 5.4.8.3. Regulatory Framework
    • 5.4.8.4. Norway Tissue Engineering Market, 2021 - 2033 (USD Billion)
  • 5.4.9. Denmark
    • 5.4.9.1. Key Country Dynamics
    • 5.4.9.2. Competitive Scenario
    • 5.4.9.3. Regulatory Framework
    • 5.4.9.4. Denmark Tissue Engineering Market, 2021 - 2033 (USD Billion)
• 5.5. Asia Pacific
  • 5.5.1. Asia Pacific Tissue Engineering Market, 2021 - 2033 (USD Billion)
  • 5.5.2. China
    • 5.5.2.1. Key Country Dynamics
    • 5.5.2.2. Competitive Scenario
    • 5.5.2.3. Regulatory Framework
    • 5.5.2.4. China Tissue Engineering Market, 2021 - 2033 (USD Billion)
  • 5.5.3. Japan
    • 5.5.3.1. Key Country Dynamics
    • 5.5.3.2. Competitive Scenario
    • 5.5.3.3. Regulatory Framework
    • 5.5.3.4. Japan Tissue Engineering Market, 2021 - 2033 (USD Billion)
  • 5.5.4. India
    • 5.5.4.1. Key Country Dynamics
    • 5.5.4.2. Competitive Scenario
    • 5.5.4.3. Regulatory Framework
    • 5.5.4.4. India Tissue Engineering Market, 2021 - 2033 (USD Billion)
  • 5.5.5. Australia
    • 5.5.5.1. Key Country Dynamics
    • 5.5.5.2. Competitive Scenario
    • 5.5.5.3. Regulatory Framework
    • 5.5.5.4. Australia Tissue Engineering Market, 2021 - 2033 (USD Billion)
  • 5.5.6. Thailand
    • 5.5.6.1. Key Country Dynamics
    • 5.5.6.2. Competitive Scenario
    • 5.5.6.3. Regulatory Framework
    • 5.5.6.4. Thailand Tissue Engineering Market, 2021 - 2033 (USD Billion)
  • 5.5.7. South Korea
    • 5.5.7.1. Key Country Dynamics
    • 5.5.7.2. Competitive Scenario
    • 5.5.7.3. Regulatory Framework
    • 5.5.7.4. South Korea Tissue Engineering Market, 2021 - 2033 (USD Billion)
• 5.6. Latin America
  • 5.6.1. Latin America Tissue Engineering Market, 2021 - 2033 (USD Billion)
  • 5.6.2. Brazil
    • 5.6.2.1. Key Country Dynamics
    • 5.6.2.2. Competitive Scenario
    • 5.6.2.3. Regulatory Framework
    • 5.6.2.4. Brazil Tissue Engineering Market, 2021 - 2033 (USD Billion)
  • 5.6.3. Argentina
    • 5.6.3.1. Key Country Dynamics
    • 5.6.3.2. Competitive Scenario
    • 5.6.3.3. Regulatory Framework
    • 5.6.3.4. Argentina Tissue Engineering Market, 2021 - 2033 (USD Billion)
• 5.7. MEA
  • 5.7.1. MEA Tissue Engineering Market, 2021 - 2033 (USD Billion)
  • 5.7.2. South Africa
    • 5.7.2.1. Key Country Dynamics
    • 5.7.2.2. Competitive Scenario
    • 5.7.2.3. Regulatory Framework
    • 5.7.2.4. South Africa Tissue Engineering Market, 2021 - 2033 (USD Billion)
  • 5.7.3. Saudi Arabia
    • 5.7.3.1. Key Country Dynamics
    • 5.7.3.2. Competitive Scenario
    • 5.7.3.3. Regulatory Framework
    • 5.7.3.4. Saudi Arabia Tissue Engineering Market, 2021 - 2033 (USD Billion)
  • 5.7.4. UAE
    • 5.7.4.1. Key Country Dynamics
    • 5.7.4.2. Competitive Scenario
    • 5.7.4.3. Regulatory Framework
    • 5.7.4.4. UAE Tissue Engineering Market, 2021 - 2033 (USD Billion)
  • 5.7.5. Kuwait
    • 5.7.5.1. Key Country Dynamics
    • 5.7.5.2. Competitive Scenario
    • 5.7.5.3. Regulatory Framework
    • 5.7.5.4. Kuwait Tissue Engineering Market, 2021 - 2033 (USD Billion)

Chapter 6. Competitive Landscape

• 6.1. Company/Competition Categorization
• 6.2. Company Position Analysis, 2025
• 6.3. Strategy Mapping
• 6.4. Company Profiles/Listing
  • 6.4.1. Zimmer Biomet Holdings, Inc.
    • 6.4.1.1. Overview
    • 6.4.1.2. Financial Performance
    • 6.4.1.3. Product Benchmarking
    • 6.4.1.4. Strategic Initiatives
  • 6.4.2. AbbVie Inc. (Allergan)
    • 6.4.2.1. Overview
    • 6.4.2.2. Financial Performance
    • 6.4.2.3. Product Benchmarking
    • 6.4.2.4. Strategic Initiatives
  • 6.4.3. BD
    • 6.4.3.1. Overview
    • 6.4.3.2. Financial Performance
    • 6.4.3.3. Product Benchmarking
    • 6.4.3.4. Strategic Initiatives
  • 6.4.4. B. Braun
    • 6.4.4.1. Overview
    • 6.4.4.2. Financial Performance
    • 6.4.4.3. Product Benchmarking
    • 6.4.4.4. Strategic Initiatives
  • 6.4.5. Integra LifeSciences Corporation
    • 6.4.5.1. Overview
    • 6.4.5.2. Financial Performance
    • 6.4.5.3. Product Benchmarking
    • 6.4.5.4. Strategic Initiatives
  • 6.4.6. Organogenesis Holdings Inc.
    • 6.4.6.1. Overview
    • 6.4.6.2. Financial Performance
    • 6.4.6.3. Product Benchmarking
    • 6.4.6.4. Strategic Initiatives
  • 6.4.7. Medtronic
    • 6.4.7.1. Overview
    • 6.4.7.2. Financial Performance
    • 6.4.7.3. Product Benchmarking
    • 6.4.7.4. Strategic Initiatives
  • 6.4.8. ACell, Inc.
    • 6.4.8.1. Overview
    • 6.4.8.2. Financial Performance
    • 6.4.8.3. Product Benchmarking
    • 6.4.8.4. Strategic Initiatives
  • 6.4.9. Athersys, Inc.
    • 6.4.9.1. Overview
    • 6.4.9.2. Financial Performance
    • 6.4.9.3. Product Benchmarking
    • 6.4.9.4. Strategic Initiatives
  • 6.4.10. Tissue Regenix Group plc
    • 6.4.10.1. Overview
    • 6.4.10.2. Financial Performance
    • 6.4.10.3. Product Benchmarking
    • 6.4.10.4. Strategic Initiatives
  • 6.4.11. Stryker Corporation
    • 6.4.11.1. Overview
    • 6.4.11.2. Financial Performance
    • 6.4.11.3. Product Benchmarking
    • 6.4.11.4. Strategic Initiatives
  • 6.4.12. RTI Surgical, Inc.
    • 6.4.12.1. Overview
    • 6.4.12.2. Financial Performance
    • 6.4.12.3. Product Benchmarking
    • 6.4.12.4. Strategic Initiatives
  • 6.4.13. ReproCell, Inc.
    • 6.4.13.1. Overview
    • 6.4.13.2. Financial Performance
    • 6.4.13.3. Product Benchmarking
    • 6.4.13.4. Strategic Initiatives
  • 6.4.14. Baxter International, Inc.
    • 6.4.14.1. Overview
    • 6.4.14.2. Financial Performance
    • 6.4.14.3. Product Benchmarking
    • 6.4.14.4. Strategic Initiatives